Ovid Therapeutics is a biopharmaceutical firm developing small-molecule drugs targeting neurological conditions centered on epilepsy and related seizure disorders. The company's pipeline includes OV329, a GABA-AT inhibitor in Phase 1 testing for drug-resistant epilepsy in adults and infants, and OV4071, an oral potassium-chloride cotransporter 2 activator also in Phase 1 trials for psychosis symptoms in Parkinson's disease, Lewy body dementia, and schizophrenia. The company maintains research partnerships with several pharmaceutical and academic institutions including AstraZeneca, Lundbeck, and Northwestern University.
1Y: 2.68 (+119.7%) · range 1.20–2.96
entry readiness 14 · NOT READY · exit proximity 0
Value area 2.28–2.80 · 38% of 120d volume overhead · moderate overhead
| Source | Score | Last seen |
|---|---|---|
| short-interest | 1.000 | Aug 31, 2026 |
| squeeze-risk | 0.404 | Aug 31, 2026 |
| earnings-surprise | 0.033 | Sep 11, 2026 |
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -4.95% | +3.53% | 19/20d |
| 40d | -4.95% | +3.53% | 19/40d |